Baili Tianheng: The dual antibody ADC drug for non-small cell lung cancer achieved the primary endpoint in the Phase III clinical trial.

Bailli Tianheng announced that the companys independently developed and the worlds first and only approved EGFRHER3 dual antibody ADC, Lunkangyilong monoclonal antibody/Yizekang, targets locally advanced or metastatic non-small cell lung cancer with EGFR sensitive mutations that have failed previous EGFR-TKI treatment. In the Phase III clinical trial, an independent data monitoring committee determined that the main endpoint of progression-free survival was achieved in the pre-specified interim analysis, and a trend of benefit was also observed for overall survival. This is the fourth Phase III clinical study of this dual antibody ADC to achieve its main endpoint, and it is the first Phase III clinical study of a dual antibody ADC drug to accomplish the main endpoint in the treatment of non-small cell lung cancer worldwide. Currently, this drug has received marketing approval from the National Medical Products Administration for two indications, and the application for marketing of one indication has been accepted by the CDE.